Evidence map›Paper›PMID 37605413›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2024

Replacement Dose for Overt Hypothyroidism Induced by Programmed Cell Death Protein 1 Antibodies May Be Higher than Recommended.

Qian Zhang, Yao Zhang, Huijuan Zhu, Kuanzhi Liu, Pingping Lou, Peixuan Kong, Lei Su, Shuchang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Qian ZhangDepartment of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei, 071000, China.
Yao ZhangDepartment of Endocrinology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China.
Huijuan ZhuKey Laboratory of Endocrinology of National Health and Family Planning Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Kuanzhi LiuDepartment of Endocrinology, the 3rd Hospital of Hebei Medical University, Shijia Zhuang, Hebei, 050051, China.
Pingping LouDepartment of Endocrinology, the 3rd Hospital of Hebei Medical University, Shijia Zhuang, Hebei, 050051, China.
Peixuan KongDepartment of Endocrinology, the 3rd Hospital of Hebei Medical University, Shijia Zhuang, Hebei, 050051, China.
Lei SuDepartment of Radiotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China.
Shuchang WangDepartment of Endocrinology, the 3rd Hospital of Hebei Medical University, Shijia Zhuang, Hebei, 050051, China.
Third Hospital of Hebei Medical University · CNAffiliated Hospital of Hebei University · CNPeking Union Medical College Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present recommendations, consensus, or guidelines for the replacement dosage for hypothyroidism induced by programmed cell death protein 1 (PD-1) therapy are not uniform, and there are very few special clinical trials that have examined the replacement dosage for it.

objectivesThis article illustrates the clinical characteristics of hypothyroidism induced by PD-1 antibodies (Abs) and reports the recommended replacement dosage for hypothyroidism.

methodsEighteen patients with overt primary hypothyroidism induced by PD-1 Abs (group 1) were selected from 655 patients with different tumor types. Retrospective analysis was performed on patients in group 1 and 18 patients with natural courses of overt primary hypothyroidism who were age- and sex-matched with the patients in group 1 (group 2). The replacement dosages required for the patients in the two groups were compared.

resultsThyroid dysfunction occurred in group 1 after approximately 3.0 ± 1.4 cycles of PD-1 therapy (1-6 stages), with a median time of 61.5 days. The median time of onset of hypothyroidism among all patients was 87.5 days (30-240 days). Most of the patients with hypothyroidism were asymptomatic, and the onset of hypothyroidism was independent of age, sex, TPOAb, TgAb and TSH in group 1 (P>0.05). The average replacement dosage for patients in group 1 was 1.8 ± 0.6 μg/kg/d (0.6-3.2 μg/kg/d). Multiple linear regression analysis showed that sex, age, TPOAb, TgAb and TSH were not correlated with drug dosage.

conclusionIt seemed that the average maintenance dosage of levothyroxine might need to be 1.8 μg/kg/day for patients with overt hypothyroidism induced by PD-1 Abs.

Indexed as

AntibodiesHypothyroidismImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorAdultAgedAntineoplastic Agents, ImmunologicalFemaleHormone Replacement TherapyHumansMaleMiddle AgedNeoplasmsRetrospective StudiesThyroxineAntibodiesAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorThyroxineHypothyroidismimmune checkpoint inhibitorsimmune-related adverse events (irAEs)programmed cell death protein 1 antibodiesreplacement dosage.thyroid irAEs

Identifiers

PMID37605413
OpenAlexW4386046019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.